Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Savara Inc. IR & PR Anne Erickson anne.erickson@savarapharma.com (512) 851-1366

Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Savara 차트를 더 보려면 여기를 클릭.
Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Savara 차트를 더 보려면 여기를 클릭.